Retatrutide dosage in units is a common search query, though it is important to clarify that this investigational medicine is currently dosed in milligrams (mg), not units. Retatrutide is a novel triple receptor agonist — targeting GLP-1, GIP, and glucagon receptors — under clinical evaluation for obesity and type 2 diabetes. Developed by Eli Lilly, it has demonstrated substantial weight-loss outcomes in Phase 2 trials. As of mid-2025, retatrutide is not approved by the MHRA or any other regulatory authority, and all dosing information derives exclusively from clinical trial protocols.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, administered as a once-weekly subcutaneous injection for obesity and type 2 diabetes. Phase 2 data showed mean body weight reductions of approximately 24% over 48 weeks at the highest dose.

Retatrutide is an investigational injectable peptide currently under clinical evaluation for the treatment of obesity and type 2 diabetes mellitus. Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist, meaning it simultaneously activates three distinct hormonal receptors:

• GLP-1 (glucagon-like peptide-1) receptor – promotes insulin secretion, reduces appetite, and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptor – enhances insulin release and may improve fat metabolism

• Glucagon receptor – increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies

This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters. In a Phase 2 clinical trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.; ClinicalTrials.gov: NCT04881760), participants receiving the highest dose of retatrutide demonstrated mean body weight reductions of approximately 24% over 48 weeks — among the most significant weight-loss outcomes observed in pharmacological trials to date. A separate Phase 2 trial in people with type 2 diabetes was also published in the NEJM in 2023, reporting meaningful reductions in HbA1c alongside weight loss.

Retatrutide is administered as a subcutaneous injection, typically once weekly, in a manner similar to other GLP-1-based therapies. The drug is being developed by Eli Lilly and Company and remains under active investigation. As of mid-2025, it is not approved for clinical use in the United Kingdom or elsewhere. All dosage information currently available is derived from clinical trial protocols rather than approved prescribing information, and should be interpreted within that context.

Dose Escalation Schedules and Titration Guidance

Retatrutide is dosed in milligrams, not units; one Phase 2 escalation schedule progressed from 2 mg weekly up to 12 mg weekly over 13 weeks. These figures are investigational and do not represent approved prescribing guidance.

Understanding retatrutide dosage in units first requires a clarification of terminology: in clinical trials, retatrutide doses are expressed in milligrams (mg) per weekly subcutaneous injection — not in insulin-style "units." Any future licensed formulation may use a pen device with a specific drug concentration, and the concept of "units" would only apply if a regulatory authority approved a product with unit-based dosing. Until then, all available dosing data refer to milligrams.

In the Phase 2 trial (NCT04881760; Jastreboff et al., NEJM 2023), participants were assigned to dose cohorts of 1 mg, 4 mg, 8 mg, and 12 mg once weekly, with the 8 mg and 12 mg cohorts demonstrating the greatest weight-loss efficacy. Multiple escalation regimens were studied across different trial arms and populations. The following is one example of a titration schedule used in Phase 2 protocols — it does not represent a single universal regimen, and other escalation speeds were also evaluated:

• Weeks 1–4: 2 mg once weekly (initiation dose)

• Weeks 5–8: 4 mg once weekly

• Weeks 9–12: 8 mg once weekly

• Week 13 onwards: 12 mg once weekly (where tolerated)

This gradual up-titration mirrors the approach used with approved agents such as semaglutide and tirzepatide, where slow dose escalation is essential to improve gastrointestinal tolerability. These figures are trial-specific and investigational; they do not constitute approved clinical guidance, and the precise dosing schedule for any future licensed product may differ substantially depending on the formulation and delivery device authorised by regulators.

Patients and clinicians should not attempt to extrapolate or self-administer retatrutide based on trial data. Doing so outside a supervised clinical setting carries significant safety risks and is not supported by any approved prescribing information.

Safety Considerations at Different Dose Levels

Gastrointestinal effects — particularly nausea, vomiting, and diarrhoea — are the most common adverse events, increasing in frequency at 8 mg and 12 mg doses. Additional cautions include heart rate elevation, hypoglycaemia risk, gallbladder events, and dehydration.

As with other incretin-based therapies, the safety profile of retatrutide is closely linked to the dose level administered. Clinical trial data (Jastreboff et al., NEJM 2023; Phase 2 T2D trial, NEJM 2023) indicate that gastrointestinal adverse effects are the most frequently reported side effects, particularly during dose escalation. These include:

• Nausea (most common, particularly at higher doses)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

Gastrointestinal events were generally mild to moderate in severity and tended to resolve as participants adapted to each dose level. However, incidence and severity increased at higher doses — particularly at 8 mg and 12 mg weekly — underscoring the importance of gradual titration.

Beyond gastrointestinal effects, the following safety signals and class-relevant cautions warrant attention:

• Heart rate elevation: Retatrutide's glucagon receptor agonism has been associated with modest increases in resting heart rate in Phase 2 data. This may be clinically relevant in patients with pre-existing cardiovascular conditions and should be monitored.

• Hypoglycaemia: While the risk is lower than with insulin or sulfonylureas, caution is warranted in people with type 2 diabetes, particularly those on concomitant glucose-lowering agents.

• Gallbladder and biliary events: As a class effect observed with GLP-1-based therapies, there is a potential risk of gallstones and related biliary complications. Patients should be advised to report symptoms such as right upper abdominal pain.

• Dehydration and acute kidney injury (AKI): Nausea, vomiting, and reduced fluid intake during dose escalation may lead to dehydration. Patients should be advised to maintain adequate hydration, and renal function should be monitored if they become unwell.

• Diabetic retinopathy: Rapid improvements in glycaemic control — as may occur with potent glucose-lowering agents — have been associated with worsening of diabetic retinopathy in some patients. People with pre-existing retinopathy should receive appropriate ophthalmic monitoring.

• Pregnancy and breastfeeding: Retatrutide is not indicated for use during pregnancy or breastfeeding. Trial protocols typically require effective contraception. Individuals of childbearing potential should follow the specific guidance provided by their trial team.

• Injection site reactions: Localised redness, bruising, or discomfort at the subcutaneous injection site have been reported.

When to seek urgent medical attention: Patients should seek prompt medical assessment if they experience severe or persistent abdominal pain (with or without vomiting), which may indicate pancreatitis or gallbladder disease, or if they develop signs of significant dehydration (dizziness, reduced urine output, rapid heart rate).

Longer-term safety data — including effects on thyroid function, pancreatitis risk, and cardiovascular outcomes — are still being gathered through ongoing Phase 3 trials. Until comprehensive safety data are available and regulatory approval is granted, retatrutide should only be administered within the context of an approved clinical trial.

If you experience a suspected side effect from any medicine, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Any individual experiencing concerning symptoms should seek prompt advice from their GP or treating clinician.

Retatrutide's Regulatory Status in the UK

Retatrutide has not received MHRA or EMA marketing authorisation as of mid-2025 and is not available through NHS prescribing. Access is limited to approved clinical trial participants at registered UK research sites.

As of mid-2025, retatrutide has not received marketing authorisation in the United Kingdom. It is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) — as confirmed by the MHRA's Product Information search and the Electronic Medicines Compendium (emc) — nor by the European Medicines Agency (EMA), and no European Public Assessment Report (EPAR) exists for this medicine. It has not been assessed by the National Institute for Health and Care Excellence (NICE) for clinical or cost-effectiveness. Consequently, it is not available through NHS prescribing channels, and there is no NICE-approved guidance on its use, dosage, or patient selection criteria. Readers are encouraged to check the MHRA/emc, EMA EPAR database, and NICE website for the most current status.

Eli Lilly and Company has progressed retatrutide into Phase 3 clinical trials, which are designed to generate the large-scale, long-term efficacy and safety data required to support a regulatory submission. Should these trials yield positive results, the company would be expected to submit a Marketing Authorisation Application (MAA) to the MHRA and/or EMA for review. The timeline for any potential UK approval remains uncertain.

In the interim, access to retatrutide in the UK is limited to approved clinical trial participants enrolled at registered research sites. Members of the public interested in trial participation should speak with their GP or a specialist clinician, who can advise on eligibility and refer to appropriate research centres. The NIHR Be Part of Research service (bepartofresearch.nihr.ac.uk) is the official UK resource for finding and joining legitimate clinical trials.

It is also important to highlight a growing patient safety concern: retatrutide — like other novel weight-loss agents — has begun to appear through unregulated online sources and grey-market suppliers. Purchasing or using retatrutide outside of a licensed clinical trial is not only contrary to UK medicines law but poses serious health risks, as product quality, concentration, and authenticity cannot be verified. The MHRA provides guidance on the risks of buying medicines online and how to identify legitimate suppliers. Patients are strongly advised to consult their healthcare provider before considering any unlicensed treatment, and to report suspected falsified or unlicensed products via the MHRA Yellow Card Scheme.

Frequently Asked Questions